丹葶肺心颗粒治疗哮喘缓解期疗效及对患者痰液炎症因子的影响  

Clinical effects and influence on sputum inflammatory factor of Danting Feixin Particles in treatment of asthma in remission stage

作　　者：李运奎[1] 马厚勋[1] 杨秋晨[1] 吴平[1] 肖卫[2] 

机构地区：[1]重庆医科大学附属第一医院老年病科,重庆400016 [2]荆州市第一人民医院,荆州434000

出　　处：《中药药理与临床》2017年第2期234-237,共4页Pharmacology and Clinics of Chinese Materia Medica

摘　　要：目的:研究丹葶肺心颗粒治疗哮喘缓解期疗效及对患者痰液炎症因子的影响。方法:研究对象为2012年6月到2014年6月我院收诊的140哮喘患者,均处于缓解期。抛硬币法分为2组(各70例)。对照组给予常规治疗,观察组另外服用丹葶肺心颗粒,对比两组治疗前后相关指标变化。结果:(1)治疗8周后,观察组FEV1%预计值、FEV1/FVC和PEFR值分别为(71.94±3.42%、79.99±3.57%、5.38±0.42L/s),均明显高于对照组(67.48±3.37%、72.16±3.48%、4.96±0.38L/s)。(2)治疗8周后,观察组痰液炎症因子ECP、IL-8和TNF-ɑ水平分别为(114.9±20.2μg/L、147.1±16.5ng/L、149.6±20.8ng/L),均明显低于对照组(153.2±21.8μg/L、169.4±18.5ng/L、187.6±22.9ng/L)。(3)8周的治疗期之后6个月内,观察组SGRQ评分、急性发作次数和呼吸道感染次数分别为(41.56±3.01分、1.28±0.46次、1.50±0.40次),均明显低于对照组(49.92±3.05分、2.01±0.52次、2.31±0.46次)。(4)服药期间,对照组出现5.71%的不良反应,观察组2.86%。结论:丹葶肺心颗粒有助于改善处于哮喘缓解期的患者肺通气指标和炎症水平,降低发病次数。Objective： To analyse clinical effects and influence on sputum inflammatory factor of Danting Feixinn Particles in treatment of asthma in remission stage. Methods： 140 patients with asthma in remission stage from June 2012 to June 2014 were grouped two groups according to coin toss method,each with 40 eases. The control group were treated with general therapy, and observation group was treated another with Danting Feixinn Particles. Correlation index of two groups were compared. Results： ① After 8 weeks of treatment, FEV1% predicted value, FEV1/ FVC and PEFR of observation group were （71.94 ± 3.42% ,79.99 ± 3.57 % ,5.38 ± 0.42L/s ） , significantly higher than that of control group （ 67.48 ± 3.37%, 72.16 ± 3.48% ,4.96 ± 0.38L/s） （ all P 〈 0.05 ）. ② After 8 weeks of treatment, ECP, IL-8 and TNF-α level in sputum of observation group were（ 114.9 ± 20.2μg/L, 147.1 ± 16.5ng/L, 149.6 ± 20.8ng/L）, significantly lower than that of control group（ 153.2 ± 21.8p.g/L, 169.4 ± 18.5ng/L, 187.6 ± 22.9ng/L） （ all P 〈 0. 05）. ③ 6 months after the treatment period of 8 weeks, SGRQ score, acute ep- isode times and respiratory infection times of observation group were （41.56 ± 3.01 points, 1.28 ± 0.46times, 1.50 ± 0.40times）, lower than that of control group （ 49.92 ± 3.05points ,2.01 ± 0.52times ,2.31 ± 0.46times） （ all P 〈 0.05 ）. ④During treatment, proportion of adverse re- actions of control group was 5.71% and observation group with 2.86% （P 〉 0.05）. Conclusion ： Danting Feixinn Particles can improve pul- monary ventilation index,inflammation level and reduce the incidence of patients with asthma in remission stage.

关 键 词：丹葶肺心颗粒 哮喘缓解期 痰液炎症 

分 类 号：R285.6[医药卫生—中药学]